Abstract
The incidence of cholesterol crystal embolism (CCE) has increased along with increases in the prevalence of atheromatous diseases and intravascular procedures. CCE frequently results in the deterioration of renal function, which sometimes leads to end-stage renal failure. Although there has been no established therapy for CCE, the possibility that low-density lipoprotein apheresis (LDL-A) is an effective therapy for renal CCE was previously reported. However, whether LDL-A improves renal CCE remains uncertain. This study aimed to evaluate the effectiveness of LDL-A in renal CCE patients. Twelve renal CCE patients (9 men and 3 women, mean age 70.6 ± 1.7 years) were included in this retrospective study. All patients had received LDL-A therapy, and estimated glomerular filtration rate (eGFR) values were examined before and after LDL-A. In addition, monthly changes in eGFR before and after LDL-A were calculated for each patient. At initial diagnosis of renal CCE, the eGFR was 35.2 ± 4.8 mL/min/1.73 m2. At the initiation of LDL-A, the eGFR significantly decreased to 11.0 ± 1.2 mL/min/1.73 m2, and monthly changes in eGFR reached −7.2 ± 2.5 mL/min/1.73 m2/month. After the initiation of LDL-A, the progression of renal dysfunction stabilized in nearly two-thirds of patients, and monthly changes in eGFR after LDL-A significantly diminished to −0.3 ± 0.7 mL/min/1.73 m2/month (p < 0.05 vs. before LDL-A). Although 4 patients had to undergo hemodialysis, all patients were alive over 1 year after the initiation of LDL-A. LDL-A therapy ameliorated renal dysfunction in renal CCE patients.
Similar content being viewed by others
References
Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375:1650–60.
Scolari F, Tardanico R, Zani R. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000;36:1089–109.
Sulowicz W, Stompor T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant. 2003;18:v59–62.
Sanai T, Matsui R, Hirano T. LDL apheresis for cholesterol embolism following coronary artery bypass graft surgery: a case report. Angiology. 2006;57:379–82.
Enomae M, Takeda S, Yoshimoto K, Takagawa K. Chronic cholesterol crystal embolism with a spontaneous onset. Intern Med. 2007;46:1123–6.
Kojima S, Ogi M, Yoshitomi Y, Kuramochi M, Ikeda J, Naganawa M, Hatakeyama H. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis. Int J Artif Organs. 1997;20:178–83.
Ardiles L, Cardenas A, Burgos ME, Droguett A, Ehrenfeld P, Carpio D, Mezzano S, Figueroa CD. Antihypertensive and renoprotective effect of the kinin pathway activated by potassium in a model of salt sensitivity following overload proteinuria. Am J Physiol Renal Physiol. 2013;304:F1399–410.
Scolari F, Ravani P, Gaqqi R, Santostefano M, Rollino C, Stabellini N, Colla L, Viola BF, Maiorca P, Venturelli C, Bonardelli S, Faqqiano P, Barrett BL. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation. 2007;116:298–304.
Japan nephrology society. Special issue. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012; 54: 1034–191.
Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231:57–61.
Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12:1781–7.
Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987;38:769–84.
Mamenko M, Zaika O, Doris PA, Pochynyuk O. Salt-dependent inhibition of ENaC-mediated sodium reabsorption in the aldosterone-sensitive distal nephropathy by bradykinin. Hypertension. 2012;60:1234–41.
Woolfson RG, Lachmann H. Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet. 1998;351:1331–2.
Scolari F, Ravani P, Pola A. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol. 2003;14:1584–90.
Lien YP, Bartholomew JR. Atheromatous embolization. Vasc Med. 2005;10:309–26.
Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33:840–50.
Hara S, Asada Y, Fujimoto S, Marutsuka K, Hatakeyama K, Sumiyoshi A, Eto T. Atheroembolic renal disease: clinical findings of 11 cases. J Atheroscler Thromb. 2002;9:288–91.
Bartholomew JR, Olin JW. Atheromatous embolization. In: Young JR, Olin JW, Bartholomew JR, editors. Peripheralvascular diseases. St Louis: Mosby; 1996. p. 261–72.
Acknowledgments
We would like to thank Dr. Aizan Hirai for valuable discussions.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hirai, K., Ookawara, S., Miyazawa, H. et al. Low-density lipoprotein apheresis ameliorates monthly estimated glomerular filtration rate declines in patients with renal cholesterol crystal embolism. J Artif Organs 18, 72–78 (2015). https://doi.org/10.1007/s10047-014-0801-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-014-0801-1